July 20, 2016 02:41 PM EDTUpdated September 18, 11:34 PM
Bioregnum
Opinion

BioReg­num: An­oth­er great rea­son emerges for As­traZeneca to tar­get new biotech deals

Bioreg­num
The view from End­points

The pres­sure on As­traZeneca CEO Pas­cal So­ri­ot to get its glob­al R&D op­er­a­tion to per­form while ex­e­cut­ing new …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

A service from the Financial Times